Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$6.70 USD
-0.34 (-4.83%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.65 -0.05 (-0.75%) 6:28 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRSN 6.70 -0.34(-4.83%)
Will MRSN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRSN
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Other News for MRSN
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN ...
Mersana Therapeutics trading halted, news pending
MRSN Trading Halted Due to Pending News
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split | MRSN Stock News
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Split | MRSN Stock News